Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TELA Bio (TELA) Other Non-Current Liabilities (2018 - 2025)

Historic Other Non-Current Liabilities for Bio (TELA) over the last 8 years, with Q3 2025 value amounting to $1.6 million.

  • Bio's Other Non-Current Liabilities rose 678.08% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year increase of 678.08%. This contributed to the annual value of $1.4 million for FY2024, which is 1750.74% down from last year.
  • As of Q3 2025, Bio's Other Non-Current Liabilities stood at $1.6 million, which was up 678.08% from $1.2 million recorded in Q2 2025.
  • Over the past 5 years, Bio's Other Non-Current Liabilities peaked at $1.7 million during Q4 2023, and registered a low of $8000.0 during Q1 2021.
  • Its 5-year average for Other Non-Current Liabilities is $1.1 million, with a median of $1.3 million in 2022.
  • Per our database at Business Quant, Bio's Other Non-Current Liabilities skyrocketed by 1692500.0% in 2022 and then crashed by 1878.27% in 2025.
  • Quarter analysis of 5 years shows Bio's Other Non-Current Liabilities stood at $380000.0 in 2021, then skyrocketed by 223.95% to $1.2 million in 2022, then skyrocketed by 36.88% to $1.7 million in 2023, then fell by 17.51% to $1.4 million in 2024, then grew by 12.16% to $1.6 million in 2025.
  • Its Other Non-Current Liabilities stands at $1.6 million for Q3 2025, versus $1.2 million for Q2 2025 and $1.3 million for Q1 2025.